Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583330 | 0.93 | MEN1 (0.37) | PLA2G4ALTB4RCYSLTR2CYSLTR1MEN1 | |
| SCHEMBL3587526 | 0.89 | CCR5 (0.39) | PLA2G4ALTB4RCYSLTR2CYSLTR1MEN1 | |
| SCHEMBL3596120 | 0.89 | MEN1 (0.45) | MEN1KMT2AACHELMNASMN1; SMN2 | |
| SCHEMBL3597678 | 0.88 | PLA2G4A (0.37) | PLA2G4ALTB4RCYSLTR2CYSLTR1MEN1 | |
| SCHEMBL3591945 | 0.87 | CCR5 (0.38) | PLA2G4ALTB4RACHELMNA | |
| SCHEMBL3600226 | 0.86 | MEN1 (0.50) | MEN1KMT2AACHELMNASMN1; SMN2 | |
| SCHEMBL3594694 | 0.86 | PLA2G4A (0.41) | PLA2G4ALTB4RCYSLTR2CYSLTR1MEN1 | |
| SCHEMBL3599652 | 0.85 | MEN1 (0.38) | MEN1KMT2AACHELMNASMN1; SMN2 | |
| SCHEMBL3591661 | 0.85 | MEN1 (0.41) | MEN1KMT2AACHEKCNJ1LMNA | |
| SCHEMBL3586234 | 0.84 | ACHE (0.43) | MEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | PLA2G4A 2410/4885LTB4R 218/4885CYSLTR2 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.